Targets of Tumor Immunity After Allogeneic Hematopoietic Stem Cell Transplantation

The effectiveness of allogeneic hematopoietic stem cell transplantation for hematologic malignancies results from the donor immunity to antigens expressed in leukemia cells in the recipient. Similar immune responses have now been identified in patients with renal cell cancer with tumor regression after allogeneic hematopoietic stem cell transplantation. Further studies to identify relevant antigens and mechanisms of resistance may improve the effectiveness of this approach in patients with solid tumors.

[1]  Jeffrey K. Mito,et al.  C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients , 2008, Clinical Cancer Research.

[2]  P. Pedrazzoli,et al.  Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors , 2008, Nature Clinical Practice Oncology.

[3]  J Philip McCoy,et al.  Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. , 2008, The Journal of clinical investigation.

[4]  Y. Kodera,et al.  Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions , 2007, Cancer science.

[5]  G. Rabinovich,et al.  Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.

[6]  J. Ritz,et al.  Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. , 2007, Blood.

[7]  Catherine J. Wu,et al.  Induction of tumor immunity following allogeneic stem cell transplantation. , 2006, Advances in immunology.

[8]  Catherine J. Wu,et al.  Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. , 2004, Blood.

[9]  E. Warren,et al.  A Human Minor Histocompatibility Antigen Resulting from Differential Expression due to a Gene Deletion , 2003, The Journal of experimental medicine.

[10]  Mark M. Davis,et al.  Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia , 2000, Nature Medicine.

[11]  D. Neuberg,et al.  Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.

[12]  J. Dick,et al.  CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.